Posted: 05/09/2025 03:25 am
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on treatments for central nervous system diseases, has recently faced significant challenges compounded by an ongoing investigation over its failed Phase 2B study for treatment-resistant depression. Despite these hurdles, executive compensation remains a pivotal aspect of the company’s financial landscape.
Timothy C. Dec, the Senior Vice President and Chief Financial Officer of Supernus, saw his total compensation for 2024 reach approximately $2.95 million. This included a base salary of $486,821, with substantial allocations in stock ($658,200) and option awards ($864,507). Additionally, incentive plan compensation and other compensations accounted for a sizable portion of his total earnings. This level of remuneration is notably amidst a turbulent period when the company's clinical trials have not delivered the expected outcomes^1.
Analyzing past compensations, Padmanabh P. Bhatt, Ph.D., the Senior Vice President and Chief Scientific Officer, had a total compensation of approximately $1.47 million in 2023, seeing a gradual increase from $1.12 million in 2022. This growth reflects consistent investment in top-tier talent despite the company's fluctuating fortunes^2^,3.
Supernus's recent challenges were underscored by a significant 14% drop in share value following the announcement that its phase 2B study for the drug SPN-820 failed to meet its primary endpoint. This study targeted treatment-resistant depression, and its results did not show statistically significant improvement over placebo^4. Following this setback, the law firm Levi & Korsinsky has commenced an investigation into potential securities fraud violations, further stressing the company's financial and operational environment^5.
Despite these adversities, Supernus reported earnings of $0.42 per share for Q1 2025, surpassing analyst expectations which stood at $0.38. This was an improvement compared to similar periods in the previous year, highlighting operational strengths amidst clinical and legal challenges^6. As of the latest data, Supernus's stock is trading at $31.54, reflecting a 1.93% increase, yet is still within the wider context of a year's low of $25.53 and a high of $40.28^7.
In essence, Supernus Pharmaceuticals is navigating through a complex landscape characterized by pending legal matters and executive compensation strategies that mirror both precaution and resilience. As investigations continue, stakeholders remain vigilant about potential implications for the company's strategic direction.
:
1. Supernus Pharmaceuticals, Inc. SEC filing for 2024 compensation [SEC Archive](https://www.sec.gov/Archives/edgar/data/1356576/000110465925042531/0001104659-25-042531-index.htm).
2. Supernus Pharmaceuticals, Inc. SEC filing for 2023 compensation [SEC Archive](https://www.sec.gov/Archives/edgar/data/1356576/000110465924054023/0001104659-24-054023-index.htm).
3. Supernus Pharmaceuticals, Inc. SEC filing for 2022 compensation [SEC Archive](https://www.sec.gov/Archives/edgar/data/1356576/000110465923054333/0001104659-23-054333-index.htm).
4. Supernus Pharmaceuticals, Inc. Press release on trial outcomes [Globe Newswire](https://www.globenewswire.com/news-release/2025/02/18/2354281/0/en/Supernus-Announces-Topline-Results-from-Phase-2B-Study-in-Adults-with-Treatment-Resistant-Depression.html).
5. Levi & Korsinsky Press release concerning ongoing investigation [Access Newswire](https://www.accessnewswire.com/newsroom/en/business-and-professional-services/levi-and-korsinsky-reminds-supernus-pharmaceuticals-inc.-investo-1025379).
6. Supernus Pharmaceuticals, Inc. Q1 2025 Earnings Report [Zacks](https://www.zacks.com/stock/news/2463438/supernus-pharmaceuticals-supn-q1-earnings-and-revenues-surpass-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2463438).
7. Current stock market data snapshot for Supernus Pharmaceuticals, Inc. [NASDAQ](https://www.nasdaq.com/market-activity/stocks/supn).
